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AT = Attention.

The Interaction between Nicotine and Negative Symptoms in
Schizophrenia and Bipolar Disorder
Bernajane M. Palisoc, McNair Scholar, Psychology & Biology Major
Dr. Daniel N. Allen, Mentor, Department of Psychology
Department of Psychology, University of Nevada, Las Vegas

Introduction

Method

• Individuals with psychiatric conditions, such as schizophrenia (SZ) and
bipolar disorders (BD), have a higher rate of smoking and have lower quit
rates compared to the general population.
• As a dopamine agonist, nicotine may help alleviate negative symptoms by
increasing abnormally low levels of dopamine in the prefrontal cortex and
mesolimbic system consistent with the dopamine deficit hypothesis
• The purpose of the study is to further explore the interactions of nicotine
and negative symptoms in a diverse population of individuals with serious
mental illness.
• Furthermore, research examining interactions of nicotine and negative
symptoms for individuals with schizophrenia compared to individuals with
bipolar disorder who experience psychotic symptoms has not been
conducted to our knowledge
• Consistent with the continuum of psychosis conceptualizations, the current
study will examine rates of smoking in SZ and BP with psychotic features
in order to provide additional information about shared symptoms and
liabilities that may link schizophrenia and bipolar disorders.
Hypothesis
• Based on the mechanism of nicotine, the current study expected higher
rates of nicotine usage in groups experiencing negative symptoms as
measured by the the Scale for the Negative Symptoms (SANS).
• Specifically, we expect SZ and BDP to have similar behavioral patterns on
our assessments and nicotine usage due to the similarity of their
symptomatic features. In contrast, we expect BDN to have a lower rate of
nicotine usage due to its lower level of negative symptoms compared to SZ
and BDP.
Table 1. Demographic Information by Group
Total
Bipolar Disorder
BDN
BDP
38.3(12.8) 38.0(13.3) 36.0(12.6)
Age
Gender (% male)
Ethnicity (%)
Caucasian
African American
Hispanic/Latino
Asian American
Biracial

37.9
42.1
11.0
5.52
1.38
4.14

29.2
39.6
4.20
2.10
0.00
8.33

29.8
36.2
2.10
8.0
2.10
4.00

Schizophrenia

F

p

40.8(12.8)

1.71
λ
0.06
0.16

0.18
p
0.57
0.16

54.0
50.0
26.0
16.0
2.00
8.00

Method
Participants:
• 48 individuals diagnosed with BDN, 47 individuals diagnosed with BDP,
and 50 individuals diagnosed with SZ.
• Demographic information for each group can be found in Table 1.
• There were no significant differences between groups on age, gender, or
ethnicity.
Questions regarding this poster should be addressed to daniel.allen@unlv.edu

Results

Measures and Procedures
• Structured Clinical Interview for DSM-IV (SCID) was used to confirm diagnoses.
Participants were then asked if they currently used tobacco; those who endorsed tobacco
use were categorize as the nicotine group while those who do not smoke were put in the
non-nicotine group. The current study examined current usage of nicotine.
• Negative Symptoms were evaluated using the Scale for the Negative Symptoms
(SANS), which can be divided into two subscales, including motivation/pleasure and
emotional expressivity.
• The Hamilton Depression Rating Scale (HDRS) was used to measure symptoms of
depression; higher ratings indicate more severe or more frequent symptoms.
Data Analysis:
• Principal Component Analysis (PCA) with varimax rotation was used to identify
groupings of SANS subscales.
• A multivariate ANOVA was used to evaluate differences between groups, smokers, and
HDRS on SANS Factor Scores. Differences between smokers on HDRS was also
measured.
• Correlation between SANS Factor Scores and HDRS were conducted for the total
sample.
Table 2. Differences Between Groups on SANS Factor Scores Using MANOVA
SZ
BDN
BDP
SANS Factors
1
0.27 (1.29)
-0.23 (0.73)
-0.06 (0.84)
2
0.10 (1.14)
0.03 (0.98)
-0.04 (0.81)
3
0.31 (1.27)
-0.27 (0.36)
-0.08 (1.01)
4
0.17 (1.14)
-0.21 (0.83)
0.02 (0.95)
5
0.16 (1.32)
-0.15 (0.64)
-0.02 (0.73)
6
0.51 (1.16)
-0.27 (0.85)
-0.03 (0.70)

F

p

3.33
0.59
4.13
1.77
1.14
11.1

0.04
0.56
0.02
0.18
0.32
0.00

Notes: SZ= Schizophrenia; BDN = Bipolar Disorder without Psychosis; BDP = Bipolar Disorder with Psychosis; Factor 1 =
Affective Flattening; Factor 2 = Anhedonia-Asociality; Factor 3 = Alogia; Factor 4 = Avolition-Apathy; Factor 5 = Affective
Flattening, Alogia, and Avolition-Apathy; Factor 6 = Attention;

Table 3. Differences Between Nicotine Usage on HDRS and SANS Factor Scores Using MANOVA
SZ
BDN
BDP
F
Smoker Non-smoker Smoker Non-smoker Smoker Non-smoker
10.6 (5.57) 7.92 (5.43) 7.78 (3.90) 9.33 (6.90) 9.92 (5.42) 8.11 (8.05)
0.72
HDRS

p
0.61

SANS Factors

1
2
3
4
5
6

0.13 (1.32)

0.41 (1.25)

-0.18 (0.83)

-0.28 (0.63)

-0.12 (0.80)

0.01 (0.88)

1.57

0.17

0.26 (1.22)

-0.07 (1.06)

0.17 (1.11)

-0.12 (0.84)

0.23 (0.99)

-0.30 (0.63)

0.96

0.45

0.29 (1.18)

0.33 (1.35)

-0.25 (0.34)

-0.28 (0.38)

-0.01 (1.28)

-0.14 (0.74)

1.74

0.13

0.38 (1.18)

-0.05 (1.09)

-0.31 (0.86)

-0.11 (0.79)

0.14 (1.12)

-0.10 (0.78)

1.41

0.22

0.32 (1.83)

-0.01 (0.80)

-0.22 (0.49)

-0.08 (0.78)

-0.00 (0.68)

-0.04 (0.77)

0.77

0.57

0.36 (1.11)

0.65 (1.20)

-0.35 (0.58)

-0.18 (1.11)

-0.26 (0.66)

-0.29 (0.73)

4.70

0.00

Notes: SZ= Schizophrenia; BDN = Bipolar Disorder without Psychosis; BDP = Bipolar Disorder with Psychosis; Factor 1 =
Affective Flattening; Factor 2 = Anhedonia-Asociality; Factor 3 = Alogia; Factor 4 = Avolition-Apathy; Factor 5 = Affective
Flattening, Alogia, and Avolition-Apathy; Factor 6 = Attention; HDRS = Hamilton Depression Rating Scale

Table 4. Correlation Between SANS Factor Scores and HDRS
SANS Factors
1
2
3
4
HDRS
r-value
-0.14
0.41**
-0.03
0.30**

5

6

0.09

0.14

Notes: Factor 1 = Affective Flattening; Factor 2 = Anhedonia-Asociality; Factor 3 = Alogia; Factor 4 = Avolition-Apathy; Factor 5
= Affective Flattening, Alogia, and Avolition-Apathy; Factor 6 = Attention; HDRS = Hamilton Depression Rating Scale;
**Correlation is significant at the 0.01 level (2-tailed).

• Based on the criteria of Kaiser-Guttman, PCA indicated that the SANS
subscales is composed of six factors:
•
•
•
•
•
•

Factor 1 measures Affective Flattening
Factor 2 measures Anhedonia-Asociality
Factor 3 measures Alogia
Factor 4 measures Avolition-Apathy
Factor 5 measures Affective Flattening, Alogia, and Avolition-Apathy
Factor 6 measures Attention

• Factor scores measuring affective flattening, alogia, and attention were
significantly different between groups (see Table 2).
• Attention was significantly different between nicotine and non-nicotine
group (see Table 3).
• There were no significant differences between nicotine and non-nicotine
group on HDRS total scores.
• SANS Factor Scores measuring anhedonia and avolition significantly
correlated with HDRS total scores (see Table 4).

Discussion
• Results suggested that the only difference in negative symptoms among
the groups was for attention
• When the sample is divided into more homogenous subsets based on
diagnostic category and nicotine usage, differential patterns of
relationships of nicotine on attention were found. Specifically:
• In schizophrenia, non-smoking and smoking were associated
with attention.
• In bipolar disorder, non-smoking and smoking were not
associated with attention.
• Findings also indicate supporting evidence for the continuum
conceptualization of psychosis.
• Similar to schizophrenia, we found bipolar disorder with psychosis to
have lower emotional expressivity compared to bipolar disorder without
psychosis.
• Findings also indicate that the SANS preserves its ability to measure
negative symptoms in a mixed clinical sample.
• Results must be considered in the context of their limitations. First,
cause and effect cannot be inferred because no participants were
randomly assigned.
• Furthermore, hypotheses regarding long-term vs. short term usage of
nicotine could not be examined because past usage was not recorded.
• Additionally, these results were obtained in a population of
symptomatically stable out-patients, and therefore do not necessarily
extend to individuals with more severe symptoms.
• Future studies should included questionnaire assessing pattern of
smoking, such as the Fagerström Test for Nicotine Dependence, when
evaluating nicotine usage and may attempt to examine any relationship
between nicotine and antipsychotic medications and their interaction on
the negative symptoms of schizophrenia and bipolar disorder.

